Showing results (1551-1560 of 1,568) with videos related to

Sort By:
Pageof 157
Nature Genetics|April 6, 2023
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancerArvind Ravi, Matthew D Hellmann, Monica B Arniella, et al.
ESMO Open|January 8, 2025
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patientsE A Martino, S Palmieri, M Galli, et al.
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|September 20, 2025
A multicentre study to compare previous and new breast dosimetry for Digital Mammography, Digital Breast Tomosynthesis and Contrast Enhanced MammographyLaura Soprani, Valentina Ravaglia, Sara Dalmonte, et al.
The Lancet. Respiratory Medicine|May 13, 2024
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trialEric Lim, David Waller, Kelvin Lau, et al.
Hematological Oncology|May 24, 2022
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trialsAntonella Bruzzese, Daniele Derudas, Monica Galli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2024
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAE Felip, B C Cho, V Gutiérrez, et al.
The New England Journal of Medicine|September 9, 2025
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLCJames Chih-Hsin Yang, Shun Lu, Hidetoshi Hayashi, et al.
Cancer Discovery|April 16, 2023
A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant MalignanciesPrabhjot S Mundi, Filemon S Dela Cruz, Adina Grunn, et al.
Nature Genetics|June 20, 2018
A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumorsMariano J Alvarez, Prem S Subramaniam, Laura H Tang, et al.
The New England Journal of Medicine|June 26, 2024
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLCByoung C Cho, Shun Lu, Enriqueta Felip, et al.
Pageof 157